An FDA-appointed advisory panel to review drug-eluting stents could have detrimental effects on the $6 billion-a-year market, reports the Chicago Sun Times, but, according to columnist Francine Knowles, Morgan Stanley analyst Glenn Reicin claims there’s no cause for alarm.
FDA says more formally evaluate recent stent studies that linked DES to the development of blood clots within 18 months. European researchers have recently concluded that older and less expensive bare-metal stents, are safer than DES and result in less blood clotting.